The U.S. Centers for Medicare and Medicaid Services “fully anticipate[s]” applying a Medicare Part B reimbursement rate next year of average sales price ASP plus 6% to drugs and biologicals purchased through the 340B program, CMS announced late this afternoon.
…
A federal appeals court ruled unanimously this morning that a South Carolina health center has the right to challenge the legality of the government’s 340B patient definition in a lower federal court.
Bausch Health this afternoon became the 18th drug manufacturer to impose conditions on 340B pricing when covered entities use contract pharmacies.
The U.S. Supreme Court ruled unanimously this morning that the federal government unlawfully slashed Medicare Part B drug reimbursement for many 340B hospitals by almost 30 percent during 2018 and 2019.
The federal government told drug manufacturer Merck today its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop, or the company could face penalties of up to $6,323 per each
…
Emeka Egwim, a federal government HIV/AIDS policy specialist who also has served in the Medicaid Drug Rebate Program, is the new head of the federal 340B Drug Pricing Program.
A federal district judge in Wilmington, Del., today struck down and vacated the federal government’s finding that drug maker AstraZeneca’s conditions on 340B pricing when covered entities uses contract pharmacies violates the 340B statute.
For the first time since the 340B contract pharmacy impasse started over a year and half ago, the leader of an influential hospital group said publicly today her association is prepared to move in the direction of a federal legislative
…
Bristol Myers Squibb (BMS) yesterday became the 12th drug manufacturer to impose restrictions on 340B pricing when hospitals and grantee covered entities contract with pharmacies to dispense drugs to patients.
AbbVie today announced conditions on 340B pricing when hospitals’ contract pharmacies dispense medicines to patients. The federal government has filed notices of appeal in Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics’ 340B contract pharmacy lawsuits.
*Sign up for news summaries and alerts from 340B Report
